Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.62 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.62 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.62 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.62 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.62 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.62 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.62 |
| ▸ | GABRP | O00591 | 1/20 | 0.62 |
| ▸ | GABRD | O14764 | 1/20 | 0.62 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.62 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.62 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.62 |
| ▸ | GABRE | P78334 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.62 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.62 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3774341 | 0.97 | TSHR (0.65) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| Hydrochloric Acid SCHEMBL27508984 | 0.94 | TSHR (0.62) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| Bromide SCHEMBL27312283 | 0.94 | TSHR (0.62) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| Hydrochloric Acid SCHEMBL27430608 | 0.94 | TSHR (0.62) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| Hydrochloric Acid SCHEMBL28132000 | 0.92 | TSHR (0.59) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| Piperazine SCHEMBL28251749 | 0.91 | CHRNB2 (0.54) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL11126760 | 0.89 | TSHR (0.56) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL9253898 | 0.87 | TSHR (0.54) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL3709913 | 0.87 | TSHR (0.54) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL30479173 | 0.87 | CHRNB2 (0.52) | TSHRGABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022227743-A1 | MEMANTINE UREA DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 沈阳药科大学 | 2022-11-03 | — | — | WO | disclosed |
| EP-2483277-B1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-9175009-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150094347-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-04-02 | — | — | US | disclosed |
| US-8952043-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | GENETECH, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2784078-A1 | Benzoxepin pi3k inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-20140135308-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8673952-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2014-03-18 | — | — | US | disclosed |
| WO-2013096744-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130012488-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BLAQUIERE NICOLE (US) | 2013-01-10 | — | — | US | disclosed |
| US-8263633-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2012-09-11 | — | — | US | disclosed |
| EP-2483277-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011103715-A1 | TASK CHANNEL ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011106276-A1 | TASK CHANNEL ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011036284-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110076291-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012488-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3R2 | TSHR 4597/4885GABRA1 1422/4885GABRG2 1087/4885 |
| US-20110076291-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, NR2E1, NR2E3 | TSHR 2806/4885GABRA1 2014/4885GABRG2 1476/4885 |
| US-20150094347-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, NR2E1, NR2E3 | TSHR 2806/4885GABRA1 2014/4885GABRG2 1476/4885 |
| US-20140135308-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, NR2E1, NR2E3 | TSHR 2806/4885GABRA1 2014/4885GABRG2 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.